Table 1 Baseline demographics and clinical characteristics
Overall PSP cohort (N = 275) | Provincial drug coverage subset (n = 113) | |||
|---|---|---|---|---|
Age, years | ||||
Mean (SD) | 57.6 (13.5) | 64.6 (12.6) | ||
Median (IQR) | 59.0 (50.0–68.0) | 68.0 (59.0–72.0) | ||
Female, n (%) | 154 (56.0%) | 65 (57.5%) | ||
Index year, n (%) | ||||
2016 | 70 (25.5%) | 25 (22.1%) | ||
2017 | 129 (46.9%) | 56 (49.6%) | ||
2018 | 64 (23.3%) | 27–31* | ||
2019 | 12 (4.4%) | 1–5* | ||
Rural residence, n (%) | ||||
Urban | 256 (93.1%) | 104 (92.0%) | ||
Rural | 19 (6.9%) | 9 (8.0%) | ||
Income quintile, n (%) | ||||
Q1, lowest | 50 (18.2%) | 29 (25.7%) | ||
Q2 | 51 (18.6%) | 16 (14.2%) | ||
Q3 | 52 (18.9%) | 18 (15.9%) | ||
Q4 | 64 (23.3%) | 24 (21.2%) | ||
Q5, highest | 58 (21.1%) | 26 (23.0%) | ||
Highest eosinophil count values† | n = 259 (94.2%) | n = 108–112* | ||
Mean (SD) | 925.3 (1275.7) | 894.7 (1295.6) | ||
Median (IQR) | 620.0 (400.0–1010.0) | 600.0 (325.0–950.0) | ||
Median eosinophil count values‡ | n = 259 (94.2%) | n = 108–112* | ||
Mean (SD) | 540.4 (491.9) | 457.8 (464.1) | ||
Median (IQR) | 400.0 (200.0–700.0) | 400.00 (200.0–600.0) | ||
Charlson Comorbidity Index, n (%) | 95 (34.5%) | 45 (39.8%) | ||
Low 0–1 | 64 (23.3%) | 24 (21.2%) | ||
Moderate 2–3 | 23 (8.4%) | 14–18* | ||
High 4+ | 8 (2.9%) | 3–7* | ||
Missing | 180 (65.5%) | 68 (60.2%) | ||